This protocol addresses men aged 18 years and older with genital lichen sclerosus whose disease has not responded adequately to first-line topical corticosteroid therapy, or for whom that class of treatment is contraindicated.
Clinical scenario: Male patient, age 18 or older, with confirmed genital lichen sclerosus — specifically where potent topical corticosteroid treatment has proven insufficient or cannot be used.
First-line management of male genital lichen sclerosus involves ultrapotent or potent topical corticosteroids (clobetasol propionate or mometasone furoate) used alongside topical emollients. Escalation to this next-line protocol is indicated when that course fails to achieve the expected goals: improvement of the clinical grade of phimosis and clearance of penile lichen sclerosus signs and symptoms.
When potent topical corticosteroids are insufficient or contraindicated, current guidance supports considering a topical calcineurin inhibitor as a second-choice or adjunctive option. The complete protocol — specifying which agent to use, how, and under what conditions — is available via the link below.
Treatment goal: Suppression of symptoms, including pruritus, burning, and dyspareunia.
We recommend ultrapotent or potent topical corticosteroids in men with genital lichen sclerosus.
We suggest topical calcineurin inhibitors in men with genital lichen sclerosus as second choice or as an additional treatment if topical corticosteroids are contraindicated or insufficient. (off label)
In conclusion, TCIs twice daily for at least 12 weeks have some effect in suppressing symptoms (pruritus, burning, dyspareunia) in LS; however, clinical signs are usually better treated by potent topical steroids.
View source ↗